03-8262. Annual Guidance Agenda  

  • Start Preamble

    AGENCY:

    Food and Drug Administration, HHS.

    ACTION:

    Notice.

    SUMMARY:

    The Food and Drug Administration (FDA) is publishing its annual guidance document agenda. FDA committed to publishing, on an annual basis, a list of possible topics for future guidance document development or revision during the next year, and seeking public comment on additional ideas for new guidance documents or revisions of existing ones. This commitment was made in FDA's September 2000 good guidance practices (GGPs) final rule, which sets forth the agency's policies and procedures for the development, issuance, and use of guidance documents. This list is intended to seek public comment on possible topics for guidance documents and possible revisions to existing guidance.

    Start Printed Page 16524

    DATES:

    Submit written or electronic comments on this list and on agency guidance documents at any time.

    ADDRESSES:

    Submit written comments to the Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to http://www.fda.gov/​dockets/​ecomments.

    Start Further Info

    FOR FURTHER INFORMATION CONTACT:

    For general information regarding FDA's GGPs contact: Diane Sullivan-Ford, Office of Policy (HF-26), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-3480. For information regarding specific topics or guidance, please see contact persons listed in the table in the SUPPLEMENTARY INFORMATION section.

    End Further Info End Preamble Start Supplemental Information

    SUPPLEMENTARY INFORMATION:

    Background

    In the Federal Register of September 19, 2000 (65 FR 56468), FDA published a final rule announcing its GGPs, which set forth the agency's policies and procedures for the development, issuance, and use of guidance documents. The agency adopted the GGPs to ensure public involvement in the development of guidance documents and to enhance public understanding of the availability, nature, and legal effect of such guidance.

    As part of FDA's effort to ensure meaningful interaction with the public regarding guidance documents, the agency committed to publishing an annual guidance document agenda of possible guidance topics or documents for development or revision during the coming year. The agency also committed to soliciting public input regarding these and additional ideas for new topics or revisions to existing guidance documents (65 FR 56468 at 56477, 21 CFR 10.115(f)(5)).

    The agency is neither bound by this list of possible topics nor required to issue every guidance document on this list or precluded from issuing guidance documents not on the list set forth in this document.

    The following list of guidance topics or documents represents possible new topics or revisions to existing guidance documents that the agency is considering. The agency solicits comments on the topics listed in this document and also seeks additional ideas from the public.

    The guidance topic or documents are organized by the issuing center or office within FDA and are further grouped by topic categories. The agency's contact persons are listed for each guidance in the following table.

    Title/Topic of GuidanceContact
    I. CENTER FOR BIOLOGICS EVALUATION AND RESEARCH (CBER)
    CATEGORY—COMPLIANCE AND INSPECTION
    Guidance for Industry: Reprocessing, Reworking and Blending of Biological Drug Substances and Drug ProductsStephen M. Ripley, Center for Biologics Evaluation and Research (HFM-17), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852-1448, 301-827-6210
    Guidance for Industry: Process Validation Considerations for Biological Drug Substances and Biological Drug ProductsSame as above (Do)
    Guidance for Industry: Sterile Drug Products Produced by Aseptic ProcessingDo
    Guidance for Industry: Design, Installation and Operation of Heating, Ventilation and Air Conditioning (HVAC) Systems Used in the Manufacture of Products Regulated by the Center for Biologics Evaluation and Research and the Center for Drug Evaluation and ResearchDo
    Guidance for Industry: Content and Format of the Warnings/Precautions Section of Labeling for Drugs and BiologicsDo
    Guidance for Industry: Content and Format of the Pregnancy and Lactation Sections of Labeling for Drugs and BiologicsDo
    Guidance for Industry and Reviewers: Measuring Patient Reported Outcomes to Support Medical Product Claims in Labeling and AdvertisingDo
    Compliance Program 7341.001 Inspections of Licensed Therapeutic Drug ProductsDo
    Compliance Program 7341.002—Inspection of Tissue EstablishmentsDo
    Compliance Program 7342.001—Inspection of Licensed and Unlicensed Blood Banks, Brokers, Reference Laboratories, and ContractorsDo
    Compliance Program 7342.002—Inspection of Source Plasma EstablishmentsDo
    Compliance Program 7342.006—Inspection of Plasma Derivatives of Human OriginDo
    Compliance Program 7342.008—Inspections of Licensed Viral Marker Test KitsDo
    Start Printed Page 16525
    Compliance Program 7345.001—Inspection of Licensed Allergenic ProductsDo
    Compliance Program 7345.002—Inspection of Licensed VaccinesDo
    CATEGORY—THERAPEUTICS
    Submission of Information for the National Xenotransplantation Database (NXD)Do
    Guidance for Reviewers: Instructions and Template for Chemistry, Manufacturing, and Controls Reviewers of Human Gene Therapy Investigational New Drug ApplicationsDo
    Guidance for Reviewers: Instructions and Template for Chemistry, Manufacturing, and Controls Reviewers of Human Somatic Cell Therapy Investigational New Drug ApplicationsDo
    Potency Assays for Therapeutic VaccinesDo
    Good Review Practices—Track IVDo
    Submission of Information for Adverse Event and Annual Reports for Gene Therapy Investigational New Drug Applications
    Mechanisms of Regulation for Products Used in the Manufacture of Cellular ProductsDo
    Submission of Chemistry, Manufacturing, and Controls Information for a Therapeutic Recombinant DNA-Derived Product or a Monoclonal Antibody for In Vivo UseDo
    Submission of Chemistry, Manufacturing, and Controls Information for Synthetic Peptide SubstancesDo
    Submission of Chemistry, Manufacturing, and Controls Information and Establishment Description for Autologous Somatic Therapy ProductsDo
    CATEGORY—BLOOD AND BLOOD COMPONENTS
    Blood Establishment SoftwareDo
    Apheresis GuidanceDo
    Uniform Donor History QuestionnaireDo
    Quality Control of Bacterial ContaminationDo
    Content of Premarket Submissions (Instruments)Do
    Medication DeferralsDo
    Validation of Computer CrossmatchDo
    Blood Contact MaterialsDo
    Red Blood Cell RepositoriesDo
    Rapid Human Immunodeficiency Virus TestsDo
    Submission of Chemistry, Manufacturing, and Controls and Establishment Description Information for Human Plasma-Derived Biological Products, Animal Plasma or Serum-Derived Products Blood Donor Testing for Syphilis Format and Content of a Biologics License Application for Immune Globulin Intravenous Recommendations for Deferral of Donors of Vaccinated With Smallpox Nucleic Acid Testing for Human Immunodeficiency Virus and Hepatitis C Virus; Testing, Product Disposition, Donor Deferral and ReentryDo
    CATEGORY—VACCINES
    Guidance for Industry: Characterization and Qualification of Cell Substances and Viral Seeds Used to Produce Viral VaccinesDo
    Start Printed Page 16526
    Guidance for Industry: Preclinical Toxicity Studies for Prophylactic VaccinesDo
    Guidance for Industry: Immunization Human Plasma Donors to Obtain Source Plasma for Preparation of Specific Immune GlobulinsDo
    Guidance for Industry: Content and Format of Chemistry, Manufacturing, and Controls Information and Establishment Description Information for a Vaccine or Related ProductDo
    Guidance for Industry on the Content and Format of Chemistry, Manufacturing, and Controls Information and Establishment Description Information for an Allergenic Extract or Allergen Patch TestDo
    CATEGORY—OTHER
    Providing Regulatory Submission in Electronic Format—StabilityDo
    Environmental Assessment/National Environmental Policy ActDo
    Requests for Engagement of Independent ConsultantDo
    Eligibility Determination for Donors of Human Cells, Tissue and Cellular and Tissue-Based Products (HCT/Ps)Do
    Filing and Application When the Applicant Protests a Refusal to File ActionDo
    Guidance for Industry: Multi-Product Manufacturing With Spore-Forming MicroorganismsDo
    II. CENTER FOR DEVICES AND RADIOLOGICAL HEALTH (CDRH)
    CATEGORY—PREMARKET REVIEW—PROCEDURAL
    Delegation of Investigational Device Exemption (Withdrawal)Joanne R. Less, Center for Devices and Radiological Health (HFZ-403), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-594-1190
    Overdue Investigational Device Exemption Annual Progress Report Procedures (Withdrawal)Do
    Humanitarian Device Exemptions (HDE) Regulation: Questions and Answers (Revised)Do
    Guidance for the Medical Device Industry on Premarket Approval Application Shell Development and Modular Review (Revised)Thinh Nguyen, Center for Devices and Radiological Health (HFZ-402), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-594-2186
    Modifications to Devices Subject to Premarket Approval Application—The Premarket Approval Application Supplement Decision Making Process (Final)Do
    Real-Time Review Program for Premarket Approval Application (PMA) Supplements (Revised)Do
    Pre-Premarket Approval Application MeetingsDo
    A New 510(k) Paradigm—Alternate Approaches to Demonstrating Substantial Equivalence in Premarket Notifications (Revised)Heather Rosecrans, Center for Devices and Radiological Health (HFZ-404), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-594-1190
    Frequently Asked Questions on the New 510(k) Paradigm (Revised)Do
    New Section 513(f)(2)—Evaluation of Automatic Class III Designation (Revised)Do
    Implementation of Third Party Programs Under the Food and Drug Modernization Act of 1997 (Revised)Ronald Parr, Center for Devices and Radiological Health (HFZ-220), Food and Drug Administration, 1350 Piccard Dr., Rockville, MD 20850, 301-443-6597, ext. 109
    Statistical Guidance on Reporting Results From Studies Evaluating Diagnostic Tests: Draft Guidance for Industry and FDA ReviewersKristen Meier, Center for Devices and Radiological Health (HFZ-542), Food and Drug Administration, 1350 Piccard Dr., Rockville, MD 20850, 301-827-4369
    Start Printed Page 16527
    CATEGORY—PREMARKET REVIEW ANESTHESIOLOGY, DENTAL, INFECTION CONTROL, AND GENERAL HOSPITAL DEVICES
    Biological Indicator (Final)Chiu S. Lin, Center for Devices and Radiological Health (HFZ-480), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-443-8913
    Chemical Indicator (Draft)Do
    Medical Sterilization Packaging (Final)Do
    Antimicrobial Coated Medical Devices (Draft)Do
    Surgical Masks (Final)Do
    Surgical Drapes and Gowns (Draft)Do
    Disinfectants to Reprocess Hemodialyzer Machine and Water Treatment Systems (Draft)Do
    Medical Glove Expiration Dating (Final)Do
    Chemotherapy Glove (Draft)Do
    Intraoral Snoring and Sleep Apnea Devices (Final)Kevin Mulry, Center for Devices and Radiological Health (HFZ-480), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-827-5283, ext. 185
    Sonography and Jaw Tracking (Final)Mary S. Runner, Center for Devices and Radiological Health (HFZ-480), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-827-5283
    Precious Metal Dental AlloysMike Adjodha, Center for Devices and Radiological Health (HFZ-480), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-827-5283
    Base Dental AlloysDo
    Dental Curing LightDo
    Periodontal Membrane GuidanceRobert Betz, Center for Devices and Radiological Health (HFZ-480), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-827-5283
    Guidance for Bone Filling and Augmentation DevicesPam Scott, Center for Devices and Radiological Health (HFZ-480), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-827-5283
    Cutaneous O2 and CO2 Monitors (Final)Joanna Weitershausen, Center for Devices and Radiological Health (HFZ-480), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-443-8611
    General Anesthesia Guidance DocumentDo
    Pulse Oximeter Guidance Document (Revised)Do
    Vascular Access Flush DevicesPatricia Cricenti, Center for Devices and Radiological Health (HFZ-480), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-594-1287, ext. 169
    Needleless Injection DevicesVon Nakayama, Center for Devices and Radiological Health (HFZ-480), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-594-1287
    CATEGORY—PREMARKET REVIEW FOR CARDIOVASCULAR DEVICES
    Intravascular Stents (Revised)Ashley Boam, Center for Devices and Radiological Health (HFZ-450), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-443-8243
    Percutaneous Transluminal Coronary Angioplasty Catheters, Class II Special Control GuidanceDo
    Start Printed Page 16528
    Cardiovascular Intravascular Filters (Revised)Elisa Harvey, Center for Devices and Radiological Health (HFZ-450), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-443-8262
    Arrhythmia DetectorsElias Mallis, Center for Devices and Radiological Health (HFZ-450), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-443-8517
    Medical Device Labeling—Suggested Format and Content (Withdrawal)Robert Gatling, Center for Devices and Radiological Health (HFZ-402), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-594-1190, ext. 140
    Class II Special Control Guidance Document: Extracorporeal Life Support Devices (Draft)Dina J. Fleischer, Center for Devices and Radiological Health (HFZ-450), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-443-8517, ext. 176
    CATEGORY—PREMARKET REVIEW FOR CLINICAL LABORATORY DEVICES
    Over-the-Counter (OTC) Drugs of AbuseArleen Pinkos, Center for Devices and Radiological Health (HFZ-440), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-594-1243
    Glucose Test SystemsPat Bernhardt, Center for Devices and Radiological Health (HFZ-440), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-594-1243
    Automated Coagulation DevicesValerie Dada, Center for Devices and Radiological Health (HFZ-440), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-594-1293
    Analytical and Clinical Validation of Multiplex Tests for Heritable DNA Markers and/or MutationsElizabeth Mansfield and Michele Schoonmaker, Center for Devices and Radiological Health (HFZ-440), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-594-1293
    Class II Special Controls Guidance Document: Specific Bacteriophage, Antibody Conjugates, and Antigens for Antibody Detection for Bacillus anthracis and Yersinia pestisRoxanne Shively, Center for Devices and Radiological Health (HFZ-440), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-594-2096
    Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems (Final)Sally Selepak, Center for Devices and Radiological Health (HFZ-440), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-594-2096
    Draft Guidance on In Vitro Diagnostic (IVD) Device StudiesJean Toth-Allen, Center for Devices and Radiological Health (HFZ-312), Food and Drug Administration, 2904 Gaither Rd., Rockville, MD 20850, 301-594-4723, ext. 141
    CATEGORY—PREMARKET REVIEW FOR GENERAL, RESTORATIVE AND NEUROLOGICAL DEVICES
    Guidance for Thermal Ablation Device 510(k)s; Draft Guidance for Industry and FDABinita Ashar, Center for Devices and Radiological Health (HFZ-410), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-594-1307
    Class II Exempt Special Controls Guidance for Various Orthopedic Fixation Devices; Final Guidance for IndustryHollace Rhodes, Center for Devices and Radiological Health (HFZ-410), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-594-2036
    Class II Special Controls Guidance Document: Knee Joint Patellofemorotibial and Femorotibial Metal/Polymer Porous-Coated Uncemented ProsthesesPeter Allen, Center for Devices and Radiological Health (HFZ-410), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-594-2036
    Class II Special Controls Guidance Document: Surgical SutureAnthony Watson, Center for Devices and Radiological Health (HFZ-450), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-594-3090
    Class II Special Controls Guidance Document: Processed Human Dura Mater (Draft)Charles Durfor, Center for Devices and Radiological Health (HFZ-410), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-594-3090
    Class II Special Controls Guidance Document: Vascular and Neurological Embolization Devices (Draft)Stephen Rhodes, Center for Devices and Radiological Health (HFZ-410), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-594-3090
    Start Printed Page 16529
    Guidance for Saline, Silicone Gel, and Alternative Breast Implants (Revised)Samie Allen, Center for Devices and Radiological Health (HFZ-410), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-594-3090
    Class II Special Controls Guidance Document: Resorbable Calcium Salt Bone Void Filler Device (Final)Nadine Sloan, Center for Devices and Radiological Health (HFZ-410), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-594-1296
    Class II Special Controls Guidance Document: Transcutaneous Electrical Stimulator for Cosmetic Use (Draft)Robert DeLuca, Center for Devices and Radiological Health (HFZ-450), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-594-1296
    Class II Special Controls Guidance Document: Cutaneous Electrode (Draft)Do
    Class II Special Controls Guidance Document: Electroconductive Media (Draft)Do
    Class II Special Controls Guidance Document: Powered Muscle Stimulator for Muscle Conditioning (Draft)Do
    Class II Special Controls Guidance Document: Powered Muscle Stimulator for Rehabilitation (Draft)Do
    Class II Special Controls Guidance Document: Transcutaneous Electrical Nerve Stimulator for Pain Relief (Draft)Do
    Special Control Guidance for Premarket Notifications for Totally Implanted Spinal Cord Stimulators for Pain Relief (Withdrawal)Kristen Bowsher, Center for Devices and Radiological Health (HFZ-450), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-594-1296
    Guidance for Technical Reporting in the Submission of Research and Marketing Applications for Totally Implanted Spinal Cord Stimulators (Draft)Do
    CATEGORY—PREMARKET REVIEW FOR OPHTHALMIC AND ENT DEVICES
    Class II Special Controls Guidance Document: Rigid Gas Permeable (RGP) by Contact Lens Finishing LaboratoriesJames F. Saviola, Center for Devices and Radiological Health (HFZ-460), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-594-1744
    Premarket Notification (510(k)) Guidance Document for Class II Daily Wear Contact Lenses (Revised)Do
    Class II Special Controls Guidance Document: Artificial Eye Care ProductsDo
    Class II Special Controls Guidance Document: Intraocular Gases for Retina TamponadeDo
    Retinal Implants: Guidance for Investigational Device Exemptions (IDE) and Premarket Approval (PMA) Applications (Draft)Do
    Guidance for Premarket Approval Applications of Class III Extended Wear Contact LensesDo
    Guidance for Post Approval Studies of Class III Extended Wear Contact Lenses Worn Beyond Seven Continuous NightsDo
    Labeling Guidance for Ultraviolet Absorbing Contact LensesDo
    Intraocular Lens Guidance DocumentDonna R. Lochner, Center for Devices and Radiological Health (HFZ-460), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-594-2053
    Refractive Implants Guidance DocumentDo
    Guidance Document for Keratomes and Keratome BladesEverette T. Beers, Chief, Center for Devices and Radiological Health (HFZ-460), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-594-2018
    Start Printed Page 16530
    Implantable Middle Ear Hearing Device (Final)Eric C. Mann, Center for Devices and Radiological Health (HFZ-460), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-594-2018
    Tinnitis Masking DevicesDo
    Laryngoplastic Phonosurgery DevicesDo
    Ear Plug DevicesDo
    CATEGORY—PREMARKET REVIEW FOR REPRODUCTIVE, ABDOMINAL AND RADIOLOGICAL DEVICES
    Devices for Assisted Reproduction Technologies (ART)Colin M. Pollard, Center for Devices and Radiological Health (HFZ-470), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-594-1180, ext. 115
    Embolization Agents for Uterine Fibroid EmbolizationDo
    CondomsDo
    Menstrual TamponsDo
    Devices for Vacuum Assisted DeliveryDo
    Device Systems for Endometrial AblationDo
    Class II Special Controls Guidance Document: External Penile Rigidity DevicesJanine Morris, Center for Devices and Radiological Health (HFZ-470), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-594-2194, ext. 117
    Guidance for the Treatment of Prostate CancerDo
    Guidance for Urethral StentsDo
    Class II Special Controls Guidance for Home Uterine Activity Monitors (Revised)Do
    Ultrasound Coupling GelRobert A. Phillips, Center for Devices and Radiological Health (HFZ-470), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-594-1212, ext. 130
    Diagnostic UltrasoundDo
    Cleaning and Disinfection of Radiological DevicesDo
    Sheaths and Covers for Ultrasound TransducersDo
    Bone Sonometers (Revised)Do
    Class II Special Controls Guidance Document: Sorbent Hemoperfusion Systems (Draft) Bone Sonometers (Revised)Carolyn Neuland, Center for Devices and Radiological Health (HFZ-470), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-594-1220, ext. 131
    Content of Premarket Notification Submissions for Conventional and High Permeability Hemodialyzers, Hemoconcentrators, Hemofilters and Hemodiafilters (Revised)Do
    Guidance for the Content of Premarket Notifications for Hemodialysis Delivery SystemsDo
    Automated Blood Cell Separators for Therapeutic Purposes (Draft)Do
    Blood Access Devices for Hemodialysis (Draft)Do
    CATEGORY—COMPLIANCE AND INSPECTIONS
    Impact Resistance Lenses: Questions and AnswersWalter Snesko, Center for Devices and Radiological Health (HFZ-220), Food and Drug Administration, 1350 Piccard Dr., Rockville, MD 20850, 301-443-6597, ext. 120
    Medical Device Quality Systems Manual for Small Entities (Update)Joseph Puleo, Center for Devices and Radiological Health (HFZ-220), Food and Drug Administration, 1350 Piccard Dr., Rockville, MD 20850, 301-443-6597, ext. 116
    Start Printed Page 16531
    Medical Glove Guidance Manual (Update)Arthur Yellin, Center for Devices and Radiological Health (HFZ-220), Food and Drug Administration, 1350 Piccard Dr., Rockville, MD 20850, 301-443-6597, ext. 146
    Draft Guidance on Cabinet X-ray Systems Performance SpecificationsDaniel Kassidy, Center for Devices and Radiological Health (HFZ-342), Food and Drug Administration, 2904 Gaither Rd., Rockville, MD 20850, 301-594-4654, ext. 141
    Final Guidance on Civil Money PenaltiesCasper Uldriks, Center for Devices and Radiological Health (HFZ-300), Food and Drug Administration, 2904 Gaither Rd., Rockville, MD 20850, 301-594-4692
    Draft Guidance on the Reports of Corrections and Removals RegulationDo
    Draft Guidance for Field Clinical EngineersMarian Surge, Center for Devices and Radiological Health (HFZ-300), Food and Drug Administration, 2904 Gaither Rd., Rockville, MD 20850, 301-594-4720, ext. 139
    Draft Guidance on Good Laboratory Practice (GLP) for Nonclinical Laboratory StudiesRodney Allnutt, Center for Devices and Radiological Health (HFZ-300), Food and Drug Administration, 2904 Gaither Rd., Rockville, MD 20850, 301-594-4723, ext. 140
    Draft Guidance on the Submission of Abbreviated Reports on Bone Densitometer Devices Utilizing Electronic Product RadiationTom Jakub, Center for Devices and Radiological Health (HFZ-333), Food and Drug Administration, 2904 Gaither Rd., Rockville, MD 20850, 301-594-4591, ext. 151
    Implementation of the Third Party Domestic Quality System ProgramRonald Parr, Center for Devices and Radiological Health (HFZ-220), Food and Drug Administration, 1350 Piccard Dr., Rockville, MD 20850, 301-443-6597, ext. 109
    CATEGORY: CONSUMER INFORMATION
    Breast Implants: An Information UpdateNancy Leonard, Center for Devices and Radiological Health (HFZ-220), Food and Drug Administration, 1350 Piccard Dr., Rockville, MD 20850, 301-443-6597, ext. 141
    Modifications and Additions to the Policy Guidance Help System #6Charles A. Finder, Center for Devices and Radiological Health (HFZ-240), Food and Drug Administration, 1350 Piccard Dr., Rockville, MD 20850, 301-827-0009
    Modifications and Additions to the Policy Guidance Help System #7Do
    Modifications and Additions to the Policy Guidance Help System #8Do
    Modifications and Additions to the Policy Guidance Help System #9Do
    Modifications and Additions to the Policy Guidance Help System #10Do
    CATEGORY—MEDICAL DEVICE REPORTING
    Needlesticks; Medical Device Reporting Guidance for User Facilities, Manufacturers, and ImportersSharon Kapsch, Center for Devices and Radiological Health (HFZ-533), Food and Drug Administration, 1350 Piccard Dr., Rockville, MD 20850, 301-827-2982
    CATEGORY—POSTMARKET SURVEILLANCE
    Preparing a Postmarket Surveillance Plan: Guidance for ManufacturersLaura Alonge, Center for Devices and Radiological Health (HFZ-510), Food and Drug Administration, 1350 Piccard Dr., Rockville, MD 20850, 301-594-3060
    CATEGORY—OTHER
    Hospital Bed System Dimensional and Assessment Guidance to Reduce Entrapment: For Industry and Health Care FacilitiesJay A. Rachlin, Center for Devices and Radiological Health (HFZ-230), Food and Drug Administration, 1350 Piccard Dr., Rockville, MD 20850, 301-594-3174
    III. CENTER FOR DRUG EVALUATION AND RESEARCH (CDER)
    CATEGORY—ADVERTISING
    Advertising and Labeling of Treatment Investigational New Drug Application ProtocolsNancy E. Derr, Center for Drug Evaluation and Research (HFD-5), Food and Drug Administration, 1451 Rockville Pike, Rockville, MD 20852, 301-594-5400
    Start Printed Page 16532
    Patient Reported OutcomesDo
    Promotion of Combination Oral Contraceptive ProductsDo
    CATEGORY—BIOPHARMACEUTICS
    Clozapine Tablets—In Vivo Bioequivalence and In Vitro Dissolution TestingDo
    CATEGORY—CHEMISTRY
    Documentation for Antibiotics and Other Cellular Metabolites Produced by Microorganisms Modified Using Recombinant DNA TechnologyDo
    Drug Products: Chemistry, Manufacturing, and Control DocumentationDo
    Drug Substance: Chemistry, Manufacturing, and Control DocumentationDo
    CATEGORY—CLINICAL/MEDICAL
    Acne VulgarisDo
    AnalgesicsDo
    Clinical Development Programs for Metered Dose Inhaler and Dry Powder Inhalers Products—RevisedDo
    Clinical Evaluation of Drugs for the Treatment of Acute Coronary SyndromeDo
    Clinical Evaluation of Combination Estrogen/Progestin-Containing Drug Products Used for Hormone Replacement Therapy in Postmenopausal Women—RevisedDo
    Clinical Evaluation of Drugs for Neuropathic PainDo
    Clinical Evaluation of Drugs for the Treatment of Heart FailureDo
    Collection and Use of Race and Ethnicity Data in Clinical Trials for FDA Regulated ProductsDo
    Development of New Opiate FormulationsDo
    Developing Antiviral Drug for the Mitigation of Complication Associated Vaccine ImmunizationDo
    Developing Antiviral Drugs for the Treatment of SmallpoxDo
    Drug-Coated Cardiovascular StentsDo
    Evaluation of New Treatments for Diabetes MellitusDo
    GingivitisDo
    Safety Review of Clinical DataDo
    CATEGORY—CLINICAL/PHARMACOLOGYDo
    Content and Format of the Clinical Pharmacology SectionDo
    Content and Format of the Warnings and Precautions, Contradictions and Boxed Warning Sections of Prescription DrugsDo
    Immediate Release to Modified Release Dosage FormsDo
    In Vitro Drug Metabolism/Drug Interaction—Guidance for ReviewersDo
    CATEGORY—COMPLIANCE
    Current Good Manufacturing Practices for Compressed Medical Gases—RevisedDo
    Maintaining Adequate and Accurate Records During Clinical InvestigationsDo
    Start Printed Page 16533
    National Drug Code Number and Drug Product LabelsDo
    Describing How Positron Emission Tomography Drug Products May Comply With New Current Good Manufacturing Process Requirements—RevisedDo
    Sterile Drug Products Produced by Aseptic ProcessingDo
    CATEGORY—ELECTRONIC SUBMISSIONS
    Providing Electronic Submissions to the Division of Drug Marketing, Advertising, and CommunicationsDo
    Providing Electronic Submissions in Electronic Format: Marketing Applications and Related Submissions
    Providing Regulatory Submissions in Electronic Format—Annual Reports for Approved New Drug ApplicationsDo
    Providing Regulatory Submissions in Electronic Format—General ConsiderationsDo
    Providing Regulatory Submissions in Electronic Format: Postmarketing Periodic Adverse Drug Experience ReportDo
    Scope and Implementation of 21 CFR Part 11: ArchivingDo
    Scope and Implementation of 21 CFR Part 11: Audit TrailsDo
    Standards for Clinical Data SubmissionsDo
    CATEGORY—GENERICS
    Bioequivalence Studies With Clinical Endpoints for Vaginal Antifungal Drug ProductsDo
    Chemistry, Manufacturing, and Controls Documentation Unique to Radiopharmaceuticals Submitted in Abbreviated New Drug ApplicationsDo
    Generic Drug Labeling When Pediatric Labeling Information Has Been Added to the Innovator LabelingDo
    CATEGORY—GOOD REVIEW PRACTICES
    General Clinical Review TemplateDo
    CATEGORY—INVESTIGATIONAL NEW DRUG APPLICATIONS
    Consumer Product Safety Commission—Tamper Resistant Packaging for Investigational New Drug ApplicationsDo
    Pediatric Safety and Efficacy Data in Investigational New Drug ApplicationsDo
    CATEGORY—LABELING
    Drug Names and Dosage FormsDo
    Pregnancy Labeling RevisionsDo
    Submitting Proprietary Names for EvaluationDo
    CATEGORY-OVER-THE-COUNTER
    Actual Use TrialsDo
    Labeling Comprehension Studies for Over-the-Counter Drug ProductsDo
    Labeling for Over-the-Counter Human Drug ProductsDo
    Labeling Over-the-Counter Human Drug Products; Questions and AnswersDo
    Time and Extent ApplicationsDo
    Start Printed Page 16534
    CATEGORY—PRESCRIPTION DRUG USER FEE AMENDMENTS OF 2002
    Continuous Marketing Application: Pilot 1—Reviewable Units for Fast Track Products Under the Prescription Drug User Fee Amendments of 2002Do
    Continuous Marketing Application: Pilot 2—Scientific Feedback and Interactions During Drug Development of Fast Track Products Under the Prescription Drug User Fee Amendments of 2002Do
    First Cycle Review Performance: Good Review Management PrinciplesDo
    CATEGORY—PHARMACOLOGY/TOXICOLOGY
    Drug-Induced Vasculitis in Nonclinical StudiesDo
    Estimating the Safe Starting Dose for Clinical Trials of Therapeutics in Adult Healthy VolunteersDo
    Immunotoxicology Evaluation of Investigational New Drug ApplicationsDo
    Nonclinical Safety Evaluation of Pediatric Drug ProductsDo
    CATEGORY—PROCEDURAL
    Assessment of Abuse Potential of DrugsDo
    Dispute Resolution Involving Pediatric LabelingDo
    Exocrine Pancreatic Insufficiency Drug Products—New Drug Application RequirementsDo
    Process for Contracts and Written Requests Under the Best Pharmaceuticals for Children ActDo
    Qualifying for Pediatric Exclusivity Under Section 505a of the Federal Food, Drug, and Cosmetic ActDo
    Reports on the Status of Postmarketing Studies—Implementation of Section 130 of the Food and Drug Administration Modernization Act of 1997Do
    IV. CENTER FOOD SAFETY AND APPLIED NUTRITION (CFSAN)
    CATEGORY: OFFICE OF PLANTS, DAIRY FOODS, AND BEVERAGES
    Final Guidance on Juice TransportAmy Green, Center for Food Safety and Applied Nutrition (HFS-306), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740, 301-436-2025
    Draft Guidance on Use of Food Allergen Test KitsJennifer Burnham, Center for Food Safety and Applied Nutrition (HFS-306), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740, 301-436-2030
    Draft Guidance to Harmonize U.S. Aflatoxin Levels in Peanuts With Codex LevelsLauren Posnick, Center for Food Safety and Applied Nutrition (HFS-306), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740, 301-436-1639
    Compliance Policy Guide for Lead Levels in Food Based on Levels Adopted by CodexDo
    Additional Questions and Answers on Juice Hazard Analysis and Critical Control PointSamir Assar, Center for Food Safety and Applied Nutrition (HFS-235), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740, 301-436-1636
    Update the Pesticide Compliance Policy Guide to Bring It in Line With the Food Quality Protection Act of 1996 and Changes in Pesticide Programs and Policy Over the Past Few YearsMike Kashtock, Center for Food Safety and Applied Nutrition (HFS-305), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740, 301-436-2022
    Guidance for Industry: Standardized Training Curriculum for Application of Hazard Analysis and Critical Control Point Principles to Juice ProcessingDo
    Start Printed Page 16535
    Listeria monocytogenes Draft GuidanceAndreas Keller, Center for Food Safety and Applied Nutrition (HFS-306), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740, 301-436-2029
    Fresh-Cut Produce Draft GuidanceJulie Schrimpf, Center for Food Safety and Applied Nutrition (HFS-306), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740. 301-436-2031
    Small Entities Guide for the Juice Hazard Analysis and Critical Control Point RegulationsAmy Green, Center for Food Safety and Applied Nutrition (HFS-306), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740, 301-436-2025
    Juice Hazard Analysis and Critical Control Point Compliance ProgramDale Wohlers, Center for Food Safety and Applied Nutrition (HFS-306), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740, 301-436-2029
    Final Compliance Policy Guide 555.600 Filth From Insects, Rodents, and Other Pests in FoodDouglas Park, Center for Food Safety and Applied Nutrition (HFS-345), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740, 301-436-2401
    Draft Compliance Policy Guide 555.525—Fly InfestationsDo
    Draft Compliance Policy Guide 555.500—Classification of Establishment Inspection ReportDo
    Draft Compliance Policy Guide 580.100—Pest InfestationsDo
    Rescind Compliance Policy Guide 527.600 Use of Dichlorvos Strips in Milk Houses and Milk RoomsEsther Lazar, Center for Food Safety and Applied Nutrition (HFS-306), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740, 301-436-1485
    Rescind Compliance Policy Guide 527.450 Milk and Milk Products Containing PenicillinDo
    Update Compliance Policy Guide 527.400 Whole Milk, Low Fat Milk, Skim Milk—Aflatoxin M1Do
    Update Compliance Policy Guide 527.300 Pathogens in Dairy ProductsDo
    Update Compliance Policy Guide 527.200 Cheese and Cheese Products—Adulteration With FilthDo
    New Compliance Policy Guide on Vitamins A and D in Milk ProductsMonica Metz, Center for Food Safety and Applied Nutrition (HFS-306), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740, 301-436-2041
    New Compliance Policy Guide on Vat PasteurizationDo
    New Compliance Policy Guide on High Temperature/Short Time PasteurizationDo
    New Compliance Policy Guide on Soft CheesesDo
    We may either update or rescind the following:Do
    Compliance Policy Guide 527.250 Cheese Misbranding Due to Moisture and FatTo be determined (TBD)
    Compliance Policy Guide 527.500 Malted MilkTBD
    Compliance Policy Guide 527.100 Butter—Adulteration Involving Insufficient Fat ContentTBD
    Compliance Policy Guide 527.250 Cheese and Cheese Products: Misbranding Involving Net WeightsTBD
    CATEGORY: OFFICE OF FIELD PROGRAMS
    Allergen Questions and AnswersDonald Kautter, Center for Food Safety and Applied Nutrition (HFS-615), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740, 301-436-1629
    Start Printed Page 16536
    Allergen Recall Classification GuidanceDo
    Juice Hazard Analysis and Critical Control Point Regulator Guide and TrainingDo
    Spice Reconditioning Inspection GuidanceDo
    Spice Reconditioning Industry GuidanceDo
    Interstate Travel Handbooks on Sanitation of: • Railroad Servicing Areas • Vessels in Operation • Vessel Construction • Vessel Watering Points • Buses • Airlines Railroad Passenger CarsDo (pending Office of Field Programs reorganization)
    International Travel Program—Guide to Inspections of Interstate Carriers and Support FacilitiesDo
    Compliance Programs for Milk, Retail Food, and Molluscan ShellfishFaye Feldstein, Center for Food Safety and Applied Nutrition (HFS-615), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740, 301-436-1564
    Electronic Inspection System With Model Code Database, Model Inspection Form, Users' ManualDo
    Food Recovery GuidelinesDo
    Permanent Outdoor Cooking GuidelinesDo
    Temporary Food Establishments GuidanceDo
    Voluntary National Retail Regulatory Program Standards and AnnexesDo
    Program Standards Clearinghouse Questions and AnswersDo
    Conference Position Papers (Shellfish and Milk for 2003)Do
    Food Code SupplementsDo
    Center for Food Safety and Applied Nutrition Response to Conference for Food Protection RecommendationsDo
    Food Code Interpretations; Questions and AnswersDo
    Opinion Letters in Response to CorrespondenceDo
    BackgroundersDo
    Program Information Manual Additions and RevisedDo
    Letters to Industry Alerting Them to a Commodity Problem, Emerging Situations, and How to RespondDo
    Managing Food Safety: A Regulator's Guide for Applying Hazard Analysis and Critical Control Point Principles to Risk-Based Retail and Food Service InspectionsDo
    Managing Food Safety: A Guide for the Voluntary Use of Hazard Analysis and Critical Control Point Principles for Operators of Food Service and Retail EstablishmentsDo
    Combined Pasteurized Milk and Dry Milk OrdinanceDo
    Annual Report Regarding State Program Evaluations (Milk and Shellfish)Do
    Rescind Guidance Regarding Blending of Milk Products (Compliance Policy Guide?)Office of Plant and Dairy Foods and Beverages
    Compliance Policy Guide—Criteria for Refusal for Entry of Food Products From Firms That Refuse to Allow InspectionsDo
    Start Printed Page 16537
    Listeria Action PlanDonald Kautter, Center for Food Safety and Applied Nutrition (HFS-615), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740, 301-436-1629
    Food Registration ImplementationDo
    Molluscan Shellfish: Guide for the Control of Molluscan Shellfish • Model Ordinance • Public Health Reasons and Program Requirements for State Administrative Procedures; Laboratory Procedures; Growing Area Survey and Classification; Controlled Relaying; Patrol of Shellfish Harvesting Areas; Control of Harvesting; Aquaculture; Harvesting, Handling and Shipping Shellfish; Shellfish Processing • Guidance Documents on Growing Areas, Harvesting, Processing, and Distribution • Suggested Forms • Manual of FDA Interpretations of Model Ordinance RequirementsFaye Feldstein, Center for Food Safety and Applied Nutrition (HFS-615), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740, 301-436-1564
    Program No. 7303.003: Import Acidified and Low Acid Canned Foods ProgramTBD
    Program No. 7303.037: Domestic and Imported Cheese and Cheese ProductsTBD
    Program No. 7303.039: National Drug Residue Milk Monitoring ProgramTBD
    Program No. 7303.803: Domestic Food SafetyTBD
    Program No. 7303.803A: Domestic Acidified and Low-Acid Canned FoodsTBD
    Program No. 7303.819: Import Foods—General ProgramTBD
    Program No. 7303.842: Domestic Fish and Fishery Products Inspection Program (Fiscal Years 2001 and 2002)TBD
    Program No. 7303.844: Import Seafood ProductsTBD
    Program No. 7304.004: Pesticides and Industrial Chemicals in Domestic FoodsTBD
    Program No. 7304.016: Pesticides and Industrial Chemicals in Imported FoodsTBD
    Program No. 7304.018: Chemotherapeutic in Seafood Compliance ProgramTBD
    Program No. 7304.019: Toxic Elements in Foods and Foodware Import and DomesticTBD
    Program No. 7304.839: Total Diet StudyTBD
    Program No. 7304.803: Domestic Food Safety Program—Primary Project Filed in Chapter 3TBD
    Program No. 7307.001: Mycotoxins in Domestic FoodsTBD
    Program No. 7307.002: Mycotoxins in Imported FoodsTBD
    Program No.7309.006: Imported Foods and Color AdditivesTBD
    Program No. 7309.803: Domestic Food Safety Program—Primary Project Filed in Chapter 3)TBD
    Program No. 7309.808: Good Laboratory Practice (Nonclinical Laboratories)—Primary Project Filed in Chapter 48TBD
    Program No. 7309.809: Institutional Review Board Program—Primary Project Filed in Chapter 48TBD
    Start Printed Page 16538
    Program No. 7309.810: Sponsors, Contract Research Organizations and Monitors—Compliance With Regulations—Primary Project Filed in Chapter 48TBD
    Program No. 7309.811: Clinical Investigators—Primary Project Filed in Chapter 48TBD
    Program No. 7318.002: Retail Food Protection—StateTBD
    Program No. 7318.003: Milk Safety ProgramTBD
    Program No. 7318.004: Molluscan Shellfish EvaluationTBD
    Program No. 7318.029: Interstate Travel ProgramTBD
    Program No. 7321.002: Medical Foods—Import and DomesticTBD
    Program No. 7321.005: Domestic Nutrition Labeling and Education Act of 1990, Nutrient Sample Analysis, General Food Labeling ProgramTBD
    Program No. 7321.006: Infant Formula Program—Import and DomesticTBD
    Program No. 7321.007: Nutrition Labeling and Education Act of 1990 and Enforcement—ImportsTBD
    Program No. 7321.008: Dietary Supplements—Imports and DomesticTBD
    Program No. 7329.001: Domestic Cosmetics ProgramTBD
    Program No. 7329.002: Imported Cosmetics Compliance ProgramTBD
    CATEGORY: OFFICE OF NUTRITION, PRODUCTS, LABELING AND DIETARY SUPPLEMENTS
    Soy Formulas and Preterm Infants—Draft GuidanceShawne Suggs-Anderson, Center for Food Safety and Applied Nutrition (HFS-831), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740, 301-436-1783
    Petition Process for Requesting Labeling of Foods That Have Been Treated With Irradiation—Final Guidance published October 7, 2002Loretta Carey, Center for Food Safety and Applied Nutrition (HFS-822), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740, 301-436-2371
    Voluntary Labeling Indicating Whether Foods Have or Have Not Been Developed Using Bioengineering—Final GuidanceCataline Ferre-Hockensmith, Center for Food Safety and Applied Nutrition (HFS-822), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740, 301-436-2371
    Compliance ProgramsJohn Foret, Center for Food Safety and Applied Nutrition (HFS-810), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740, 301-436-1761
    Summary of Regulatory Requirements for Dietary SupplementsRobert Moore, Center for Food Safety and Applied Nutrition (HFS-811), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740, 301-436-1441
    Dietary Supplement Labeling GuideDo
    CATEGORY: OFFICE FOOD ADDITIVE AND SAFETY
    Points to Consider for the Use of Recycled Plastics in Food Packaging: Chemistry ConsiderationsKristina Paquette, Center for Food Safety and Applied Nutrition (HFS-275), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740, 202-436-3020
    Guidance for Industry: Testing Protocols for Determining Exposure to Radiolysis Products From Packaging Materials Irradiated in Contact With FoodDo
    Revised of Four Chapters of “Toxicological Principles for the Safety Assessment of Direct Food Additives and Color Additives Used in Food” (Redbook 2000)Carolyn Young, Center for Food Safety and Applied Nutrition (HFS-275), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740-3835, 202-418-3059
    Start Printed Page 16539
    Guidance to Industry: Evaluation of Allergenicity of Proteins Introduced into Bioengineered FoodsKathleen Jones, Center for Food Safety and Applied Nutrition (HFS-013), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740-3835, 301-436-1856. Guidance document reassigned with Kathleen Jones Office of Regulation and Policy (HFS-013)
    Preparing a Color Additive Petition for Submission to the Center for Food Safety and Applied Nutrition for Color Additives Used in or on Contact LensesJudy Kidwell, Center for Food Safety and Applied Nutrition (HFS-265), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740-3835, 202-418-3354
    Compliance Policy Guideline on Chloropropanols in Soy Sauces and Hydrolyzed Vegetable ProteinDo
    Guidance for Preparing a Claim of Categorical Exclusion or an Environmental Assessment for Submissions to the Center for Food Safety and Applied NutritionLayla Batarseh, Center for Food Safety and Applied Nutrition (HFS-245), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740-3835, 202-418-3016
    Guidance for Preparing a Claim of Categorical Exclusion or an Environmental Assessment for Submissions to the Center for Food Safety and Applied Nutrition (Appendix D)Do
    Guidance for Industry: Submission of Food Contact Notifications in Electronic FormatKen McAdams, Center for Food Safety and Applied Nutrition (HFS-205), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740-3835, 202-418-3392
    Submission of Premarket Biotechnology Notices (PBNs) to FDA's Office of Food Addictive Safety—Electronic Copies in Portable Document Format (PDF)Linda Kahl, Center for Food Safety and Applied Nutrition (HFS-255) Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740-3835, 202-418-3101
    Submission of Premarket Biotechnology Notices (PBNs) to FDA's Office of Food Addictive Safety—Electronic Copies in Hypertest Markup Language (HTML)Do
    Providing Food and Color Additive Petitions in Electronic FormatDo
    Guidances Under the Public Health Security and Bioterrorism Preparedness and Response Act of 2002, Title III, Subtitle A
    CATEGORY: OFFICE OF COSMETICS AND COLORS
    Labeling for Topically Applied Cosmetic Products Containing Alpha Hydroxy Acids as Ingredients—Draft GuidanceJulie Barrows, Center for Food Safety and Applied Nutrition (HFS-105), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740, 202-418-3407
    Cosmetics Handbook for Industry—Draft GuidanceBeth Meyers, Center for Food Safety and Applied Nutrition (HFS-105), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740, 202-418-3174
    Strategy for Enforcement of 21 CFR 740.10: Required Warning Statement for Cosmetics With Insufficient Data to Substantiate Safety—Draft GuidanceDo
    V. CENTER FOR VETERINARY MEDICINE (CVM)
    CATEGORY—HUMAN FOOD SAFETY
    Evaluating the Safety of Antimicrobial New Animal Drugs With Regard to Their Microbiological Effects on Bacteria of Human Health ConcernWilliam Flynn, Center for Veterinary Medicine (HFV-2), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 301-827-4514
    Mass Spectroscopy Spectrometry for Confirmation of the Identity of Drug ResiduesDavid Heller, Center for Veterinary Medicine (HFV-511), Food and Drug Administration, 8401 Muirkirk Rd., Beltsville, MD 20855, 301-827-8156
    Assessment of the Effects of Antimicrobial Drug Residues From Food of Animal Origin on the Human Intestinal FloraHaydee Fernandez, Center for Veterinary Medicine (HFV-153), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-6981
    Studies to Evaluate the Utility of Anti-Salmonella Chemical Food Additives in FeedHenry Ekperigin, Center for Veterinary Medicine (HFV-222), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-0174
    CATEGORY—NEW ANIMAL DRUG APPLICATIONS
    Start Printed Page 16540
    Development of Supplemental Applications for Approved New Animal Drugs (Section 403(b) of the Food and Drug Administration Modernization Act of 1997)Marilyn Martinez, Center for Veterinary Medicine (HFV-130), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-7577
    Administrative New Animal Drug Application ProcessGail Schmerfeld, Center for Veterinary Medicine (HFV-112), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-0205
    CATEGORY—LABELING
    Manufacture and Labeling of Raw Meat Diets for Consumption by Dogs, Cats, and Captive Non-Companion Animal Carnivores and OmnivoresWilliam Burkholder, Center for Veterinary Medicine (HFV-228), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-0179
    Labeling and Professional Flexible LabelingDouglass Oeller, Center for Veterinary Medicine (HFV-112), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-0131
    CATEGORY—TARGET ANIMAL SAFETY
    New Drug Dosage or Dosage Range CharacterizationGail Schmerfeld, Center for Veterinary Medicine (HFV-112), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-0205
    Use of Field Studies to Demonstrate the Effectiveness of a New Animal DrugSteven Vaughn and Gail Schmerfeld, Center for Veterinary Medicine (HFV-130), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-7584
    CATEGORY—STATUTORY REQUIREMENTS
    Dispute Resolution—Food and Drug Administration Modernization Act of 1997Marcia Larkins, Center for Veterinary Medicine (HFV-1), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 301-827-4535
    CATEGORY—INTERNATIONAL HARMONIZATION
    Guidance GL27 International Cooperation on Harmonization of Technical Requirements for Registration of Veterinary Medicinal ProductsWilliam Flynn, Center for Veterinary Medicine (HFV-2), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 301-827-4514
    VI. OFFICE OF THE COMMISSIONER, OFFICE FOR GOOD CLINICAL PRACTICE (OGCP)
    CATEGORY—GOOD CLINICAL PRACTICE; GUIDANCE FOR INSTITUTIONAL REVIEW BOARDS AND CLINICAL INVESTIGATORS
    Cooperative Arrangements for Institutional Review Board's Review of ResearchBonnie M. Lee, Office of the Commissioner, Office for Good Clinical Practice (HF-34), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-3340
    Institutional Review Board's Review of Research Conducted at Other SitesDo
    Continuing Review After Study ApprovalDo
    Dates of Continuing ReviewDo
    Interactions Among FDA, Sponsor, Investigator, and Institutional Review BoardDo
    Acceptance of Clinical Studies Conducted Outside the United StatesDo
    Charging for Investigational ProductsDo
    Recruiting Study SubjectsDo
    Payment to Research SubjectsDo
    Screening Tests Prior to Study EnrollmentDo
    A Guide to Informed ConsentDo
    Use of Investigational Products When Subjects Enter a Second InstitutionDo
    Start Printed Page 16541
    Personal Importation of and Use of Drug Products Not Approved in the United StatesDo
    Investigational Use of Marketed Drugs, Biologics, and Medical DevicesDo
    Emergency Use: Exceptions From the Requirements for Institutional Review Board (IRB) Review and Informed ConsentDo
    Emergency Use of an Investigational Drug or Biologic Under 21 CFR Part 312Do
    Expanded Access of Investigational DrugsDo
    Waiver of Institutional Review Board Requirements for Drug and Biologic StudiesDo
    Drug Study DesignsDo
    Evaluation of Gender Differences in Clinical InvestigationsDo
    Medical Devices 21 CFR Part 812Do
    Significant Risk and Nonsignificant Risk Medical Device StudiesDo
    Emergency Use of Unapproved Medical DevicesDo
    FDA Institutional Review Board InspectionsDo
    Clinical Investigator Regulatory SanctionsDo
    Recordkeeping in Clinical InvestigationsDo
    Significant Differences in FDA's and the Department of Health and Human Services' RegulationsDo
    A Self-Evaluation Checklist for Institutional Review BoardsDo
    VII. OFFICE OF REGULATORY AFFAIRS (ORA)
    INSPECTION GUIDES
    Techniques for Detecting False Data During Bioresearch Monitoring InspectionsGerald Miller, Division of Field Investigations (HFC-130), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-5655
    Guide to Inspections of Bulk Pharmaceutical ChemicalsDo
    Guide to International Inspections and TravelRebecca Hackett, Division of Field Investigations, (HFC-130), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD, 20857, 301-827-3777
    Guide to Produce Farm InvestigationsEllen Morrison, Emergency Operations (HFC-160), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-5660
    Start Signature

    Dated: March 28, 2003.

    Jeffrey Shuren,

    Assistant Commissioner for Policy.

    End Signature End Supplemental Information

    [FR Doc. 03-8262 Filed 4-3-03; 8:45 am]

    BILLING CODE 4160-01-S

Document Information

Published:
04/04/2003
Department:
Food and Drug Administration
Entry Type:
Notice
Action:
Notice.
Document Number:
03-8262
Dates:
Submit written or electronic comments on this list and on agency guidance documents at any time.
Pages:
16523-16541 (19 pages)
Docket Numbers:
Docket No. 03N-0094
PDF File:
03-8262.pdf